Stockwinners Market Radar for November 11, 2017 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

09:52 EDT Argos Therapeutics provides update from Phase 3 ADAPT trial - Argos Therapeutics provided an update on the immunology data from the February 2017 interim analysis of data from the ongoing Phase 3 ADAPT clinical trial evaluating Rocapuldencel-T for the treatment of metastatic renal cell carcinoma presented in the poster session at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer in National Harbor, Maryland. The presentation is focused primarily upon immunology data from the ADAPT clinical trial and includes both new data and an update to data that was previously presented at the European Society of Medical Oncology Conference in September 2017 that now includes additional patients. A total of 462 patients were enrolled in the ADAPT study and randomized 2:1 between combination treatment with Rocapuldencel-T and sunitinib versus sunitinib monotherapy. Immunology data from the February 2017 interim analysis of the data from the ADAPT study reported at the SITC Conference were pre-specified and include correlations between survival and the change from baseline in antigen-specific memory T-cells, the amount of IL-12 secreted by each patient's specific Rocapuldencel-T immunotherapy, and the percentage of regulatory T-cells at baseline, which was observed in both arms of the study. In subjects for whom immune response data were analyzed, the number of antigen-specific memory T-cells was found to increase only after administration of Rocapuldencel-T. In those subjects who received at least seven doses of Rocapuldencel-T, the average number of antigen-specific memory T-cells after the seventh dose was approximately double the number observed before treatment. This increase was found to be statistically significant. Additionally, for those subjects who received at least seven doses of Rocapuldencel-T, there was a statistically significant correlation between survival and the change in the number of antigen-specific memory T-cells from baseline. For those 25 patients with the greatest increase in the number of antigen-specific memory T-cells from baseline, no patient deaths had been recorded as of the time of the February 2017 interim analysis. Following the IDMC's interim analysis, the Company met with the FDA to discuss the ADAPT trial and the future direction of the Rocapuldencel-T program in April 2017. The FDA agreed with the company's decision to continue the ADAPT trial, and further agreed to review a protocol amendment to extend the trial beyond the originally targeted 290 events and a revised statistical analysis plan that the company plans to submit.

08:11 EDT Week in review: How Trump's policies moved stocks - Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Trump and his administration with this weekly recap compiled by The Fly: 1. TAX PROPOSALS: On Thursday, Senate Republicans unveiled their proposal to overhaul the U.S. tax code, which differs from the previously released House tax plan in several ways, according to The Wall Street Journal. Most notably, the Senate bill would delay a corporate tax rate cut until 2019, sets a 38.5% top tax rate for individuals and preserves a seven-bracket structure. In contrast, the House bill would cut the corporate tax rate to 20% immediately and has a 39.6% top rate and a four-bracket structure, the Journal noted. Meanwhile, the House Ways & Means Committee voted on Thursday to approve the tax overhaul proposal and advance it to a floor vote, according to multiple media reports. 2. PRIVATE EQUITY: Earlier this week, Morgan Stanley analyst Michael Cyprys told investors in a research note that the House GOP tax proposal would limit interest deductibility, which has led to concerns over the future of private equity use of leverage and the potential for reduced supply in the high yield bond market. However, he thinks incrementally higher LBO funding costs and interest deductibility limitations should not be a major headwind for supply. Regardless of the final shape of a tax bill, change could create market dislocations and "there will be winners and losers," Cyprys contended. He views Oaktree Capital (OAK) as best positioned for dislocation given its dry powder and skew toward distressed investing, but also sees Blackstone (BX) and Apollo Global (APO) as well positioned. 3. CRUISE LINES: Stifel analyst Steven Wieczynski attributed weakness seen in cruise line stocks on Friday to the fact that the recently released Senate tax reform bill had specific cruise language in it. However, he reminded investors that the initial House tax reform bill also had cruise specific language in it and "all of a sudden it disappeared," which is what he expects to happen in the Senate as well given the industry's lobbying power. He said he would use the weakness in shares of Carnival (CCL), Royal Caribbean (RCL) and Norwegian Cruise Line (NCLH) as a buying opportunity. 3. RUSSIAN PROBE: Russian Twitter (TWTR) accounts began heaping praise on Donald Trump and ripping his rivals within weeks after he announced his bid for the presidency in June 2015, earlier than previously thought, according to an analysis by The Wall Street Journal. The Journal analyzed 159,000 deleted tweets from accounts that Twitter identified to congressional investigators as operated by the Kremlin-backed Internet Research Agency. Meanwhile, according to a report by Business Insider, citing newly leaked documents, the Kremlin invested "hundreds of millions" in Twitter and Facebook (FB) through an associate of Jared Kushner, President Trump's son-in-law and senior adviser. The "Paradise Papers" are a new leak of 13 million documents about offshore tax havens. According to the documents, two Russian state-owned entities with close ties to Vladimir Putin invested money into Facebook and Twitter through the Russian-American tech investor Yuri Milner. "Week in Review" is The Fly's weekly recap of its recurring series of "Trump Effect" exclusive stories.